Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket

@article{Bai2012CovalentFI,
  title={Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket},
  author={Yu Bai and Huifang Xue and Kun Wang and Lifeng Cai and Jia-yin Qiu and Shuangyu Bi and Luhua Lai and Maosheng Cheng and Shuwen Liu and Keliang Liu},
  journal={Amino Acids},
  year={2012},
  volume={44},
  pages={701-713}
}
Covalent inhibitors form covalent adducts with their target, thus permanently inhibiting a physiological process. Peptide fusion inhibitors, such as T20 (Fuzeon, enfuvirtide) and C34, interact with the N-terminal heptad repeat of human immunodeficiency virus type 1 (HIV-1) gp41 glycoprotein to form an inactive hetero six-helix bundle (6-HB) to prevent HIV-1 infection of host cells. A covalent strategy was applied to peptide fusion inhibitor design by introducing a thioester group into C34-like… 
View on Springer
ncbi.nlm.nih.gov
16 Citations
Highly Influential Citations
1
Background Citations
3
Methods Citations
1

16 Citations

Citation Type

Citation Type

Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection.
A targeted covalent small molecule inhibitor of HIV-1 fusion.
TLDR
A low molecular weight covalent inhibitor targeting a conserved lysine residue within the hydrophobic pocket of HIV-1 glycoprotein-41 exhibited an order of magnitude enhancement of anti-fusion activity against HIV- 1 compared to its non-covalent counterpart.
Covalent Inhibition of HIV‐1 Integrase by N‐Succinimidyl Peptides
TLDR
The combination of a readily synthesizable peptide precursor with easy and efficient binding to the target protein makes this approach a promising new strategy for designing lead compounds.
Evaluation of the NIH clinical collection to identify potential HIV-1 integrase inhibitors
TLDR
This study resulted in the establishment of an automated Scintillation Proximity Assay (SPA), the successful screening of 727 compounds, and the availability of a platform to expedite the future screening of potential HIV-1 integrase inhibitors.
An integrated map of HIV genome-wide variation from a population perspective
TLDR
It is suggested that, in addition to the impact of protein multimerization and immune selective pressure on HIV-1 diversity, HIV-human protein interactions are facilitated by high variability within intrinsically disordered structures.
Precisely Designed Isopeptide Bridge-Crosslinking Endows Artificial Hydrolases with High Stability and Catalytic Activity under Extreme Denaturing Conditions.
Enzymes normally lose their activities under extreme conditions due to the dissociation of their active tertiary structure. If an enzyme could maintain its catalytic activity under non-physiological…
Challenges in oral drug delivery of antiretrovirals and the innovative strategies to overcome them.
Interdisciplinary characterization of T cell dynamics in HIV infection
TLDR
This thesis has combined the knowledge of immunology and virology with the help of bioinformatics to study T cell dynamics in HIV infection, and shows the power of multidisciplinary approaches, integrating complex evolutionary and immunological data, to understand the mechanisms underlying T cell dysfunction and pathogenesis.
Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections
TLDR
This review focuses on the state of the art of organic-based nanoparticles for the delivery of approved antivirals and the most promising research addressing the treatment of most important viral infections.
Synthesis and evaluation of antiviral activities of novel sonochemical silver nanorods against HIV and HSV viruses
...
1
2
...

References

SHOWING 1-10 OF 58 REFERENCES
A Covalent Inhibitor Targeting an Intermediate Conformation of the Fusogenic Subunit of the HIV-1 Envelope Complex*
TLDR
This is the first demonstration of the trapping of an intermediate conformation of a viral envelope glycoprotein during the fusion process that occurs in live cells and is projected to improve the pharmacokinetics of administration in vivo and improve the long-term sustainability of peptide entry inhibitor therapy and help to expand its applicability beyond salvage therapy.
Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.
SC29EK, a Peptide Fusion Inhibitor with Enhanced α-Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide
TLDR
The results show that the α-helicity in a peptide-based fusion inhibitor is a key factor for activity and enables the design of short peptide inhibitors with improved pharmacological properties.
Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
TLDR
The covalent trimer, (CCIZN17)3, has an extraordinary thermodynamic stability that translates into unprecedented antiviral potency and is an attractive lead to develop as an antiviral drug, alone or in combination with DP178, as a promising immunogen to elicit a fusion-blocking neutralizing antibody response.
Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus
TLDR
A series of oligomeric HR2 peptides with increased helical structure and with exceptionally high HR1/HR2 bundle stability are made and could not generate virus with decreased sensitivity, even after >70 days in culture, suggesting superior durability as compared with ENF.
Permanent inhibition of viral entry by covalent entrapment of HIV gp41 on the virus surface.
TLDR
Evidence showing that vulnerable conformational intermediates exist transiently during HIV viral entry is shown, and the details presented herein will facilitate development of envelope as a target for therapeutics and potential chemopreventive agents that could disable the virus before contact with the host cell.
Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor*
TLDR
Sifuvirtide has potential to become an ideal fusion inhibitor for treatment of HIV/AIDS patients, including those with HIV-1 strains resistant to T20, as well as the results from Phase Ia clinical studies, which suggest that sifuvIRTide has a different mechanism of action from that of T20.
Rationally Designed Anti-HIV Peptides Containing Multifunctional Domains as Molecule Probes for Studying the Mechanisms of Action of the First and Second Generation HIV Fusion Inhibitors*
TLDR
It is found that the peptide 5HR exhibited low-to-moderate inhibitory activity on HIV-1-mediated cell-cell fusion, whereas addition of LBD and/or PBD to the HR sequence resulted in a significant increase of the anti-HIV-1 activity.
Atomic structure of a thermostable subdomain of HIV-1 gp41.
TLDR
This thermostable subdomain displays the salient features of the core structure of the isolated gp41 subunit and thus provides a possible target for therapeutics designed selectively to block HIV-1 entry.
A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.
TLDR
The results suggest that both oligomerization and ordered structure are necessary for biological activity and provide insights into the role of this region in HIV infection and the potential for development of a new class of antiviral agents.
...
1
2
3
4
5
...